Oncotarget

Researchers from Schulich School of Medicine discuss the role of CEA, CA-125, and CA19-9 as adjuncts in NSCLC management. They analyze associations with radiographic responses and clinical outcomes in NSCLC patients. The study provides evidence for the clinical use of these tumor markers in guiding treatment decisions.

Researchers John F. Thompson and Gabrielle J. Williams discuss the timing of treatment for melanoma, emphasizing the importance of identifying high-risk patients early. They explore the implications of offering adjuvant therapy to patients whose melanoma may have already metastasized for better treatment outcomes.

BUFFALO, NY- June 11, 2024 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 28 years to celebrate cancer survivors, pay tribute to lives that have been lost, and to work together to support research and find a cure. THE ORIGIN OF THE RIDE The Ride for Roswell started in 1989 when Mitch Flynn, owner of the advertising agency Flynn & Friends, met Katherine Gioia. Katherine was a four-year-old patient battling a rare form of cancer. After Katherine’s death (less than a year after her diagnosis), Katherine’s mother, Anne Gioia, and aunt, Donna Gioia, founded the Roswell Park Alliance Foundation in her memory to raise money for cancer research and treatment. On June 29, 1996, Mitch and Alliance Foundation staff launched the first Ride for Roswell. In the 28 years since then, thanks to over 135,000 riders and thousands of volunteers, the Ride for Roswell has raised over $72 million to fund cancer research. The event has become one of the largest charity rides in the United States. THIS YEAR This year, Ride Day is on Saturday, June 22, 2024, and will once again begin at the University at Buffalo North Campus. There are nine routes to choose from, ranging from five to 100 mile distances. All riders are encouraged to check in on the Thursday or Friday before Ride Day. Learn more about The Ride, check in, and routes: www.rideforroswell.org/routes/ JOIN A TEAM: TEAM OPEN ACCESS Impact Journals has been a part of this event since 2018 and continues to sponsor captain Sergei Kurenov’s peloton, Team Open Access. Team Open Access was named in honor of all open-source online medical journals, such as Oncotarget, Aging, Genes & Cancer, and Oncoscience. Sergei works at Roswell Park Comprehensive Cancer Center to create, develop, and implement innovative diagnostic and surgical pre-planning software used in cancer treatment. He has been riding in the event since 2016. “I am proud to [say] that our team is supported again by open source cancer-related scientific journals: Oncotarget and Aging! Both of these journals publish high-impact research papers of general interest and biological significance in all fields of cancer research,” Sergei said. There is still time to join Team Open Access in the Ride for Roswell. You can also support the team by giving a donation of any size. Any avenue of support you may choose to donate to the Ride for Roswell will make a difference and change lives. “Finding a cure for cancer is something we are all incredibly passionate about, and we are so thankful and grateful for your support. Together, we can make a difference!” Sergei said. “Thank you so much for your donations, your support, and well wishes!” Visit the Open Access team page to join or donate today: give.roswellpark.org/site/TR/Specia…eam&fr_id=1940 For media requests, please contact media@impactjournals.com.

Dr. Blagosklonny, an expert in NSCLC treatment, discusses overcoming resistance in lung cancer therapy. He delves into the challenges with current EGFR inhibitors, the potential of Osimertinib as a third-generation TKI, and the use of preemptive combinations to enhance treatment outcomes.

Researchers explore synergistic cytotoxicity in pancreatic cancer cells by combining HDAC and PARP inhibitors with Decitabine, offering potential for novel therapeutic approaches. The study delves into the impact of specific drug combinations on pancreatic cancer cell lines, highlighting promising results for personalized treatment strategies.

Researchers from Atrium Health discuss the cardiotoxicity of BTK inhibitors, focusing on predictive biomarkers and risk stratification. Genetic markers like KCNQ1 and GATA4 show promise in identifying high-risk patients, emphasizing the need for a clinicogenomic risk model for improved patient management.

Dr. Benoit Chabot discusses the anticancer potential of CLK kinase inhibitors 1C8 and GPS167, impacting cell proliferation and gene expression. The compounds influence pathways like MIC targets, TGF beta signaling, and splicing mechanisms, potentially affecting metastasis and antiviral immune response.

Researchers from Perderzoli Hospital discuss the importance of integrated therapies on cancer, focusing on Silibinin's anti-inflammatory properties as a potential adjuvant to standard cancer treatments for reducing toxicity and improving outcomes.

Delving into the challenges of AML treatment and the search for innovative solutions to combat relapse through a new study targeting drug resistance. Exploring GHRH antagonists in treating AML and inhibiting drug-resistant leukemia cells. Investigating the efficacy of MIA-602 in combating Doxorubicin-resistant AML with promising antiproliferative effects. Discussing novel therapeutic strategies for overcoming drug resistance in AML and the importance of translating preclinical discoveries into personalized clinical treatments.

Researchers Laurence Booth, Jane L. Roberts, and others discuss GZ17-6.02's efficacy in killing uveal melanoma cells. They cover the compound's components, safety evaluations, phase I trials, interactions with inhibitors, and its impact on cell signals for tumor cell elimination.